Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simvastatin + nivolumab + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Ares
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Simvastatin + nivolumab + oxaliplatin is a combination therapy regimen under investigation for the first-line treatment of HER2-negative, ARID1A-mutated advanced gastrooesophageal carcinoma. This regimen, evaluated in the ARES Phase 2 trial sponsored by the National Cancer Institute, Naples, combines the HMG-CoA reductase inhibitor simvastatin with the PD-1-targeting monoclonal antibody nivolumab and a standard oxaliplatin-based chemotherapy backbone (such as mFOLFOX6 or XELOX). The rationale for this combination is based on evidence that ARID1A mutations may create metabolic vulnerabilities or immune-modulating effects that are enhanced by statins, potentially improving the efficacy of standard chemo-immunotherapy.
- Other names
- simvastatin + nivolumab + oxaliplatin-based chemotherapy
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on simvastatin + nivolumab + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simvastatin + nivolumab + oxaliplatin.